Watchdog: Biogenerics needed 'as quickly as possible'

As the FDA hashes out issues on regulating knockoffs of biotech drugs, or what the industry calls biosimilars, the consumer advocacy group Public Citizen makes a case in a Chicago Tribune story this week about the need for generic versions of pricey biologics. "Biotech drugs are among the world's most expensive," Sidney Wolfe, director of the health research group at Public Citizen, told the newspaper. "They have been good, but they have been expensive, so it is extraordinarily important to get biogenerics as quickly as possible." Article

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.